Ulka Vaishampayan, MD, presented “Recent Clinical Radionuclide Therapy Advances in mCRPC” for the Grand Rounds in Urology audience in February, 2020.
How to cite: Vaishampayan, Ulka. “Recent Clinical Radionuclide Therapy Advances in mCRPC” February, 2020. Accessed Jul 2024. https://grandroundsinurology.com/recent-clinical-radionuclide-therapy-advances-in-mcrpc/
Recent Clinical Radionuclide Therapy Advances in mCRPC – Summary:
Ulka Vaishampayan, MD, Professor of Oncology at Wayne State University and Chief of Solid Tumor Oncology at the Karmanos Cancer Center, discusses the phase 3 randomized controlled trial of 177-Lutetium-PSMA radionuclide therapy. In this brief summary, Dr. Vaishampayan discusses the mechanism of action of this novel therapy, how to identify patients utilizing a PSMA-based PET scan, and the inclusion/exclusion criteria from the phase 3 randomized control trial of this targeted agent.
ABOUT THE AUTHOR
Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center, in Ann Arbor, Michigan. She is Co-Leader of the Translational and Clinical Research Program in the University of Michigan Cancer Center. She is also Chair of the Southwest Oncology Group Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. She is PI of a Department of Defense Kidney Cancer Research grant and a co-PI of the Prostate Cancer Foundation Challenge award. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development. She has authored or coauthored numerous publications focusing on novel therapeutics for patients with genitourinary malignancies.
